Source comparison
CJC-1295 Fat Loss Complete Guide 2026: Comparison Table
CJC-1295 with DAC GHRH analog; binds albumin for extended half-life 1–2 mg once or twice weekly 200–300% baseline for 6–8 days Sustained GH elevation with minimal injection frequency Risk of insulin resistance above 2 mg/dose; slower onset than pulsatile proto
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC
- GHRH analog; binds albumin for extended half-life
- 1–2 mg once or twice weekly
- 200–300% baseline for 6–8 days
- Sustained GH elevation with minimal injection frequency
- Risk of insulin resistance above 2 mg/dose; slower onset than pulsatile protocols
- CJC-1295 no DAC (Mod GRF 1-29)
- GHRH analog; short half-life
- 100–200 mcg, 2–3× daily
- 200–250% baseline for 90–120 min per dose
- Mimics physiological GH pulsatility
- Requires strict dosing schedule; impractical beyond 6–8 weeks
- Ipamorelin
- Ghrelin receptor agonist (GHRP)
- 100–300 mcg, 2–3× daily
- 150–200% baseline per pulse
- Synergistic with GHRH analogs; minimal cortisol/prolactin elevation
- Weak as monotherapy; must be paired with GHRH for meaningful fat loss
- GHRP-2
- Ghrelin receptor agonist
- 250–350% baseline per pulse
- Strong GH release; amplifies GHRH effect
- Elevates cortisol and prolactin significantly; hunger stimulation limits use during deficit
- Hexarelin
- 100 mcg, 2× daily
- 300–400% baseline per pulse
- Highest GH output among GHRPs
- Rapid desensitization after 14–21 days; cortisol spike; not suitable for protocols >4 weeks